原发性肝癌患者血清sFas的检测及其意义

MEASURE AND SIGNIFICANCE OF SFAS IN THE PATIENTS WITH HEPATOCELLUL-AR CARCINOMA IN SERA

目的 :检测原发性肝癌患者血清可溶性 Fas(s Fas)的水平 ,并探讨其临床意义。方法 :采用生物素 -亲和素酶联免疫吸附试验 (Biotin- avidin enzyme- linked imm unosorbent assay,BA - EL ISA)检测来自广西的 2 7例原发性肝癌患者和 2 8例正常人血清的 s Fas。结果 :原发性肝癌组血清 s Fas水平为 (3.6 73± 1 .2 98)μg/ L ,高于正常对照组的 (2 .1 4 7± 0 .5 2 3)μg/ L (P <0 .0 5 )。肝癌患者 AFP阳性组、AFP阴性组与正常对照组血清 s Fas分别为 (3.6 5 7± 1 .0 99)μg/ L、(3.6 90± 1 .5 31 )μg/ L和 (2 .1 4 7±0 .5 2 3)μg/ L ,其中肝癌患者 AFP阳性组、AFP阴性组分别高于正常组 (P <0 .0 1 )。结论 :血清 s Fas水平增高 ,可能可作为原发性肝癌尤其是 AFP阴性的肝癌患者的诊断指标之一。

Objective:To detect the soluble Fas (sFas) level in the sera of patients with hepatocellular carcinoma, exploring their clinical significance.Methods:The levels of sFas was measured by Biotin avidin enzyme linked immunosorbent assay (BA ELISA) in sera from 27 patients with hepatocellular carcinoma from Guangxi and in sera of 28 cases of normal controls.Result:The mean levels of sFas in sera from hepatocellular carcinoma and normal control group were (3 673±1 298) μg/L,(2 147±0 523) μg/L,respectively, showing that sFas levels in the patients with hepatocellular carcinoma was significantly higher than that in normal controls (P<0 05). The mean levels of sFas in sera from hepatocellular carcinoma AFP positive group, AFP negative group and normal controls group were (3 657±1 099) μg/L ;(3 690±1 531) μg/L;(2 147±0 523) μg/L, respectively, showing that sFas levels in the patients with hepatocellular carcinoma in AFP positive group and AFP negative group were both significantly higher than that in normal control (P<0 01).Conclusion:The sFas levels in the sera of patients with hepatocellular carcinoma increase, so sFas in the sera can be served as one of diagnosis factor for hepatocellular carcinoma, especially for those patients with AFP negative.